THE B-CELL RESPONSE TO PRIMARY AND BOOSTER DOSES OF MENACWY‑CRM VACCINE ADMINISTERED AT 2, 4 AND 12 MONTHS OF AGE
ESPID Education. Blanchard-Rohner G. 06/07/11; 7769
Dr. Geraldine Blanchard-Rohner
Dr. Geraldine Blanchard-Rohner

This content is available to ESPID members only


Click here for more information or if you are considering becoming an ESPID member.

Abstract
Discussion Forum (0)
Rate & Comment (0)
The B-cell response to primary and booster doses of an investigational
MenACWY-CRMvaccine administered at 2, 4 and 12 months of age
Geraldine Blanchard-Rohner
1,2
, Matthew D. Snape
1
, Dominic F. Kelly
1
, Tessa
John
1
, Daniel O’Connor
1
, Elizabeth A. Clutterbuck
1
,Brigitte Ohene-Kena
1
, Chaam
Klinger
1
, Hannah Parks
1
, Elizabeth Kibwana
1
, Seema Brar
1
, Peter Dull
3
, Piotr
Juszczak
3
, and Andrew J. Pollard
1
1
Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK
2
University Hospital of Geneva, Geneva, Switzerland
3
Novartis Vaccines and Diagnostics, Cambridge, MA and Siena, Italy
Background and aims: A new quadrivalent meningococcal vaccine conjugated to CRM
(MenACWY-CRM) is immunogenic in young infants. In this study we assessed the
memory B-cell and antibody responses after a primary course and a booster dose of
MenACWY-CRM in infants.
Methods: 216 healthy infants were primed at 2 and 4 months of age and boosted at 12
months of age with MenACWY-CRM. Blood samples were obtained from all children at
5, 12 and 13 months of age. The memory B-cell response was measured by ELISPOT
and serum antibodies measured using a serum bactericidal assay with human complement
(hSBA).
Results: At 5 months of age, after primary immunisation, serogroup-specific memory Bcells
were detectable in fewer than 25% of children, although protective hSBA antibody
titres (≥1:8) were detectable in more than 94% of children against serogroup C and W-
135, in 87% against serogroups Y, and in 58% against serogroup A. At 12 months of age,
before booster immunisation the percentages with hSBA ≥1:8 were 2% for serogroup A,
40% for serogroup C, 59% for serogroup W-135 and 54% for serogroup Y. One month
after the booster dose of MenACWY-CRM over 50% of children had detectable memory
B-cells, more than 98% had protective antibody titres against serogroups C, W-135 and
Y, and 91% against serogroup A.
Conclusions: These data indicate that few antigen-specific anticapsular memory B-cells
can be detected after two doses priming with MenACWY-CRM, however, these cells
rapidly proliferate after booster immunisation and induce a strong bactericidal antibody
response.
Code of conduct/disclaimer available in General Terms & Conditions

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies